Pristine Solutions acquires Eaton Scientific Systems

Pristine Solutions, Inc. (OTCQB: PRTN) (OTCBB: PRTN) ("Pristine Solutions" or the "Company") is pleased to announce that the Company has completed the acquisition of Eaton Scientific Systems, Ltd., a biomedical product development company focused on women's health solutions ("Eaton Scientific").

Eaton Scientific has identified, developed, and filed a patent for a novel indication of an existing FDA approved drug, homatropine, for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.  The drug indication, that Eaton Scientific named Tropine 3, is currently being prescribed and compounded by doctors in the Los Angeles, California specifically for their patients who have hot flash symptoms and do not want to take hormonal treatment. The drug, homatropine, is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate the pupil. Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic administration. Homatropine has been prescribed continuously and safely in the United States for over 40 years.

"Every woman who has experienced hot flashes knows the devastating affects they have on themselves personally and on their loved ones.  Tropine 3 has been shown in individual cases to reduce the symptoms of hot flashes in terms of intensity, duration, and number of occurrences without the use of dangerous hormones which," said Michael Borkowski, CEO and President of Eaton Scientific Systems, Ltd. "We look forward to building market awareness and acceptance of Tropine 3 throughout the women's health care sector in hopes of improving the lives of the over 50 million women in America that would benefit from this proven safe and effective treatment for hot flashes."

The Company is currently assembling a senior management team and group of scientific advisors to assist in the ongoing development and clinical testing of Tropine 3.  Clinical trials currently being contemplated will be performed to strict FDA standards to provide support to claims made in Eaton Scientific's patent filed under USPTO #60/719,756.  Additional information regarding the near-term scheduling and commencement of planned Tropine 3 clinical trials will be made available in subsequent public statements.

Source:

Pristine Solutions, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip